Skip to main content
Menu

Posts tagged with "The Dark Side"

  • Business and Markets

    Pharma Whistleblowing: How It Works

    Here’s more detail on the case that led to Pfizer’s 2.3 billion dollar fine/settlement, courtesy of Bloomberg. Here’s how things got started, apparently: Pfizer Inc. sales folks had one tough customer in psychiatrist Stefan Kruszewski. He didn’t buy their pitch to prescribe the anti-psychotic drug Geodon to children, a use that… Read More
  • Business and Markets

    A 2.3 Billion Dollar Attention-Getter

    No sooner do I write another post about pharma marketing than Pfizer finds itself paying 3.2 2.3 billion dollars in fines for doing it improperly. 1.2 billion of that is a criminal penalty, and needless to say, they’ve set the current record. The issues were off-label promotion of Bexxtra, Geodon, Zyvox, and Lyrica, with the… Read More
  • Business and Markets

    Ghostwriting

    As much as I defend the industry I work in, I have to talk about things that we do that I don’t think are so defensible. Another one of those has come up thanks to the New York Times and PLoS Medicine, who obtained a pile of records from a current court case. This article… Read More
  • The Dark Side

    What’s With Those People at Elsevier, Anyway?

    Via a reader comes this article, which takes us to Elsevier’s hard-hitting textbook publishing operation. The co-authors of a psychology text for the publisher were recently taken aback to get this e-mail from a publicist at the company: “”Congratulations and thank you for your contribution to Clinical Psychology. Now that the boo… Read More
  • Regulatory Affairs

    Selling Zyprexa

    Well, this doesn’t look good for Lilly. A huge pile of court documents has been unsealed in the ongoing lawsuits about Zyprexa’s off-label promotion. The company has already paid some serious fines, and is now fighting it out with insurance companies and other plaintiffs who are seeking to recover their costs. Several states are suing… Read More
  • The Dark Side

    Another Sack of Raving Nonsense Is Slated For Publication

    I spoke here about Scigen, the program that’ll concoct a load of total nonsense for you and make it look – from a distance – like a journal paper. It’s a surprisingly valuable tool, since the scientific publishing world apparently has a bigger demand for total nonsense than you might think, especially after the checks… Read More
  • The Dark Side

    Word For Word – But Why?

    I missed this a couple of months ago, but there was a paper withdrawn from the Journal of Organic Chemistry. The original is here, a contribution from the Indian Institute of Chemical Technology in Hyderabad on 2-aryl benzothiazoles. The JOC editor’s note is here, and states: This manuscript was withdrawn from publication by the Editor-in-Chi… Read More
  • Business and Markets

    Perpetual Patents: A Nasty Thought Occurs

    A colleague of mine read the “Perpetual Patent” item below, and had a thought of his own. “If I were the head of a company that just discovered something like Lipitor”, he said, using the example that the Xconomy piece used as well, “I’m probably going to fire all the early stage research people. Who… Read More
  • Academia (vs. Industry)

    Competing (And Competing Unethically?)

    Sean Cutler, a biologist at UC-Riverside, is the corresponding author of a paper in a recent issue of Science. That’s always a good thing, of course, and people are willing to go to a lot of trouble to have something like that on their list of publications. But Cutler’s worried that too many scientists, especially… Read More
  • Business and Markets

    Merck, Elsevier, and Fakery

    I’ve been meaning to write about the latest advance in salesmanship, pioneered by Merck and Elsevier. As most of you will have heard, the two collaborated to produce something called “The Australasian Journal of Bone and Joint Medicine”. This appears to have looked like a real journal, complete with the Elsevier logo and a board… Read More
...212223...